MedPath

Abacavir

Generic Name
Abacavir
Brand Names
Epzicom, Kivexa, Triumeq, Trizivir, Ziagen
Drug Type
Small Molecule
Chemical Formula
C14H18N6O
CAS Number
136470-78-5
Unique Ingredient Identifier
WR2TIP26VS
Background

Abacavir (ABC) is a powerful nucleoside analog reverse transcriptase inhibitor (NRTI) used to treat HIV and AIDS. Chemically, it is a synthetic carbocyclic nucleoside and is the enantiomer with 1S, 4R absolute configuration on the cyclopentene ring. In vivo, abacavir sulfate dissociates to its free base, abacavir.

Indication

Abacavir is indicated in combination with other anti-retroviral agents for the treatment of HIV-1 infection. It is available in a combination product alongside dolutegravir and lamivudine for the treatment of adult and pediatric patients with HIV-1 who weigh ≥10 kg.

Associated Conditions
Human Immunodeficiency Virus Type 1 (HIV-1) Infection
Clinical Trials
Related News

A Study to Evaluate Various Combinations of Anti-HIV Medications to Treat Early HIV Infection

Not Applicable
Completed
Conditions
HIV Infections
First Posted Date
2001-08-31
Last Posted Date
2012-06-07
Lead Sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
Target Recruit Count
900
Registration Number
NCT00000919
Locations
🇺🇸

Univ of Southern California / LA County USC Med Ctr, Los Angeles, California, United States

🇺🇸

Marin County Specialty Clinic, San Rafael, California, United States

🇺🇸

Emory Hemo Comp Evaluation Clinic / East TN Comp Hemo Ctr, Atlanta, Georgia, United States

and more 77 locations

A Study of Abacavir Plus Indinavir Sulfate Plus Efavirenz in HIV-Infected Patients

Phase 2
Completed
Conditions
HIV Infections
First Posted Date
2001-08-31
Last Posted Date
2021-11-01
Lead Sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
Target Recruit Count
300
Registration Number
NCT00001086
Locations
🇺🇸

Johns Hopkins Hosp, Baltimore, Maryland, United States

🇺🇸

Stanford Univ Med Ctr, Stanford, California, United States

🇺🇸

Stanford at Kaiser / Kaiser Permanente Med Ctr, San Francisco, California, United States

and more 53 locations

A Study of the Effects of Amprenavir, a Protease Inhibitor, on Carbohydrate and Fat Metabolism in HIV-Infected Patients

Phase 3
Completed
Conditions
HIV Infections
First Posted Date
2001-08-31
Last Posted Date
2005-06-24
Lead Sponsor
Glaxo Wellcome
Registration Number
NCT00002245
Locations
🇺🇸

LAC / USC Med Ctr / Infectious Diseases, Los Angeles, California, United States

Treatment Success and Failure in HIV-Infected Subjects Receiving Indinavir in Combination With Nucleoside Analogs: A Rollover Study for ACTG 320

Phase 2
Completed
Conditions
HIV Infections
First Posted Date
2001-08-31
Last Posted Date
2021-10-28
Lead Sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
Target Recruit Count
440
Registration Number
NCT00000885
Locations
🇺🇸

Johns Hopkins Hosp, Baltimore, Maryland, United States

🇺🇸

Division of Inf Diseases/ Indiana Univ Hosp, Indianapolis, Indiana, United States

🇺🇸

Boston Med Ctr, Boston, Massachusetts, United States

and more 50 locations

Effectiveness and Safety of Epivir/Ziagen/Zerit (3TC/ABC/d4T) Versus Epivir/Ziagen/Sustiva (3TC/ABC/EFV) Versus Epivir/Ziagen/Agenerase/Norvir (3TC/ABC/APV/RTV) in HIV Patients Who Have Never Received Treatment

Phase 4
Conditions
HIV Infections
First Posted Date
2001-08-31
Last Posted Date
2005-06-24
Lead Sponsor
Glaxo Wellcome
Target Recruit Count
300
Registration Number
NCT00005017
Locations
🇺🇸

Jaime Hernandez, Research Triangle Park, North Carolina, United States

Comparison of Three Different Initial Treatments Without Protease Inhibitors for HIV Infection

Phase 3
Completed
Conditions
HIV Infections
First Posted Date
2001-08-31
Last Posted Date
2012-05-21
Lead Sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
Target Recruit Count
1125
Registration Number
NCT00013520
Locations
🇺🇸

The Ponce de Leon Ctr. CRS, Atlanta, Georgia, United States

🇺🇸

Northwestern University CRS, Chicago, Illinois, United States

🇺🇸

St. Louis ConnectCare, Infectious Diseases Clinic, St. Louis, Missouri, United States

and more 57 locations

Effects on the Immune System of Anti-HIV Drugs in Patients Recently Infected With HIV

Not Applicable
Completed
Conditions
HIV Infections
First Posted Date
2001-08-31
Last Posted Date
2011-03-02
Lead Sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
Target Recruit Count
288
Registration Number
NCT00001119
Locations
🇺🇸

Seattle HIVNET, Seattle, Washington, United States

🇺🇸

Univ of Washington, Seattle, Washington, United States

🇺🇸

Univ of Minnesota, Minneapolis, Minnesota, United States

and more 9 locations

Changing to Nonprotease Inhibitor Treatment to Improve Side Effects

Phase 2
Completed
Conditions
HIV Infections
Lipodystrophy
First Posted Date
2001-08-31
Last Posted Date
2011-02-28
Lead Sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
Target Recruit Count
342
Registration Number
NCT00021463
Locations
🇺🇸

Northwestern Univ Med School, Chicago, Illinois, United States

🇺🇸

Univ of Pennsylvania, Philadelphia, Pennsylvania, United States

🇺🇸

Emory Univ, Atlanta, Georgia, United States

and more 8 locations

Effectiveness of the Early Addition of Abacavir to an Anti-HIV Drug Combination

Phase 2
Completed
Conditions
HIV Infections
First Posted Date
2001-08-31
Last Posted Date
2008-09-09
Lead Sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
Target Recruit Count
80
Registration Number
NCT00001132
Locations
🇺🇸

Univ of Miami School of Medicine, Miami, Florida, United States

🇺🇸

Emory Univ, Atlanta, Georgia, United States

🇺🇸

Cook County Hosp, Chicago, Illinois, United States

and more 27 locations

Mycophenolate Mofetil and Abacavir Treatment in HIV Patients With Failed Anti-HIV Treatment

Phase 2
Withdrawn
Conditions
HIV Infections
First Posted Date
2001-08-31
Last Posted Date
2021-11-01
Lead Sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
Registration Number
NCT00021489
© Copyright 2025. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy